Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice

Haoheng Yan, Anneke C. Blackburn, S. Christine McLary, Luwei Tao, Amy L. Roberts, Elizabeth A. Xavier, Ellen S. Dickinson, Jae Hong Seo, Richard B. Arenas, Christopher N. Otis, Qing J. Cao, Rebecca G. Lawlor, Barbara A. Osborne, Frances S. Kittrell, Daniel Medina, D. Joseph Jerry

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Mutation and loss of function in p53 are common features among human breast cancers. Here we use BALB/c-Trp53+/- mice as a model to examine the sequence of events leading to mammary tumors. Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls. In addition, sporadic mammary hyperplasias were rare in BALB/c-Trp53+/- mice and not detectably different from those of wild-type controls. Among the 28 mammary tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more than 90% of invasive mammary tumors. Transplantation of Trp53+/- ductal hyperplasias also indicated an association between loss of the wild-type allele of Trp53 and progression to invasive carcinomas. Therefore, loss of p53 function seems to be a rate-limiting step in progression. Moreover, expression of biomarkers such as estrogen receptor κ, progesterone receptor, Her2/Neu, and activated Notch1 varied among mammary tumors, suggesting that multiple oncogenic lesions collaborate with loss of p53 function. Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts. Tumors expressing solely luminal or basal keratins were also observed (27 and 11%, respectively), but the largest class of tumors expressed both luminal and basal keratins (62%). Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.

Original languageEnglish
Pages (from-to)1421-1432
Number of pages12
JournalAmerican Journal of Pathology
Volume176
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Breast Neoplasms
Keratins
Hyperplasia
Neoplasms
Biomarkers
Neoplastic Stem Cells
Loss of Heterozygosity
Cell Lineage
Progesterone Receptors
Human Mammary Glands
Estrogen Receptors
Breast
Transplantation
Alleles
Carcinoma
Mutation
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Yan, H., Blackburn, A. C., McLary, S. C., Tao, L., Roberts, A. L., Xavier, E. A., ... Jerry, D. J. (2010). Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. American Journal of Pathology, 176(3), 1421-1432. https://doi.org/10.2353/ajpath.2010.090438

Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. / Yan, Haoheng; Blackburn, Anneke C.; McLary, S. Christine; Tao, Luwei; Roberts, Amy L.; Xavier, Elizabeth A.; Dickinson, Ellen S.; Seo, Jae Hong; Arenas, Richard B.; Otis, Christopher N.; Cao, Qing J.; Lawlor, Rebecca G.; Osborne, Barbara A.; Kittrell, Frances S.; Medina, Daniel; Jerry, D. Joseph.

In: American Journal of Pathology, Vol. 176, No. 3, 01.03.2010, p. 1421-1432.

Research output: Contribution to journalArticle

Yan, H, Blackburn, AC, McLary, SC, Tao, L, Roberts, AL, Xavier, EA, Dickinson, ES, Seo, JH, Arenas, RB, Otis, CN, Cao, QJ, Lawlor, RG, Osborne, BA, Kittrell, FS, Medina, D & Jerry, DJ 2010, 'Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice', American Journal of Pathology, vol. 176, no. 3, pp. 1421-1432. https://doi.org/10.2353/ajpath.2010.090438
Yan, Haoheng ; Blackburn, Anneke C. ; McLary, S. Christine ; Tao, Luwei ; Roberts, Amy L. ; Xavier, Elizabeth A. ; Dickinson, Ellen S. ; Seo, Jae Hong ; Arenas, Richard B. ; Otis, Christopher N. ; Cao, Qing J. ; Lawlor, Rebecca G. ; Osborne, Barbara A. ; Kittrell, Frances S. ; Medina, Daniel ; Jerry, D. Joseph. / Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. In: American Journal of Pathology. 2010 ; Vol. 176, No. 3. pp. 1421-1432.
@article{813001ed18f448e3a6ad68e10baad780,
title = "Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice",
abstract = "Mutation and loss of function in p53 are common features among human breast cancers. Here we use BALB/c-Trp53+/- mice as a model to examine the sequence of events leading to mammary tumors. Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls. In addition, sporadic mammary hyperplasias were rare in BALB/c-Trp53+/- mice and not detectably different from those of wild-type controls. Among the 28 mammary tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more than 90{\%} of invasive mammary tumors. Transplantation of Trp53+/- ductal hyperplasias also indicated an association between loss of the wild-type allele of Trp53 and progression to invasive carcinomas. Therefore, loss of p53 function seems to be a rate-limiting step in progression. Moreover, expression of biomarkers such as estrogen receptor κ, progesterone receptor, Her2/Neu, and activated Notch1 varied among mammary tumors, suggesting that multiple oncogenic lesions collaborate with loss of p53 function. Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts. Tumors expressing solely luminal or basal keratins were also observed (27 and 11{\%}, respectively), but the largest class of tumors expressed both luminal and basal keratins (62{\%}). Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.",
author = "Haoheng Yan and Blackburn, {Anneke C.} and McLary, {S. Christine} and Luwei Tao and Roberts, {Amy L.} and Xavier, {Elizabeth A.} and Dickinson, {Ellen S.} and Seo, {Jae Hong} and Arenas, {Richard B.} and Otis, {Christopher N.} and Cao, {Qing J.} and Lawlor, {Rebecca G.} and Osborne, {Barbara A.} and Kittrell, {Frances S.} and Daniel Medina and Jerry, {D. Joseph}",
year = "2010",
month = "3",
day = "1",
doi = "10.2353/ajpath.2010.090438",
language = "English",
volume = "176",
pages = "1421--1432",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice

AU - Yan, Haoheng

AU - Blackburn, Anneke C.

AU - McLary, S. Christine

AU - Tao, Luwei

AU - Roberts, Amy L.

AU - Xavier, Elizabeth A.

AU - Dickinson, Ellen S.

AU - Seo, Jae Hong

AU - Arenas, Richard B.

AU - Otis, Christopher N.

AU - Cao, Qing J.

AU - Lawlor, Rebecca G.

AU - Osborne, Barbara A.

AU - Kittrell, Frances S.

AU - Medina, Daniel

AU - Jerry, D. Joseph

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Mutation and loss of function in p53 are common features among human breast cancers. Here we use BALB/c-Trp53+/- mice as a model to examine the sequence of events leading to mammary tumors. Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls. In addition, sporadic mammary hyperplasias were rare in BALB/c-Trp53+/- mice and not detectably different from those of wild-type controls. Among the 28 mammary tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more than 90% of invasive mammary tumors. Transplantation of Trp53+/- ductal hyperplasias also indicated an association between loss of the wild-type allele of Trp53 and progression to invasive carcinomas. Therefore, loss of p53 function seems to be a rate-limiting step in progression. Moreover, expression of biomarkers such as estrogen receptor κ, progesterone receptor, Her2/Neu, and activated Notch1 varied among mammary tumors, suggesting that multiple oncogenic lesions collaborate with loss of p53 function. Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts. Tumors expressing solely luminal or basal keratins were also observed (27 and 11%, respectively), but the largest class of tumors expressed both luminal and basal keratins (62%). Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.

AB - Mutation and loss of function in p53 are common features among human breast cancers. Here we use BALB/c-Trp53+/- mice as a model to examine the sequence of events leading to mammary tumors. Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls. In addition, sporadic mammary hyperplasias were rare in BALB/c-Trp53+/- mice and not detectably different from those of wild-type controls. Among the 28 mammary tumors collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in more than 90% of invasive mammary tumors. Transplantation of Trp53+/- ductal hyperplasias also indicated an association between loss of the wild-type allele of Trp53 and progression to invasive carcinomas. Therefore, loss of p53 function seems to be a rate-limiting step in progression. Moreover, expression of biomarkers such as estrogen receptor κ, progesterone receptor, Her2/Neu, and activated Notch1 varied among mammary tumors, suggesting that multiple oncogenic lesions collaborate with loss of p53 function. Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts. Tumors expressing solely luminal or basal keratins were also observed (27 and 11%, respectively), but the largest class of tumors expressed both luminal and basal keratins (62%). Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.

UR - http://www.scopus.com/inward/record.url?scp=77749237125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749237125&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2010.090438

DO - 10.2353/ajpath.2010.090438

M3 - Article

VL - 176

SP - 1421

EP - 1432

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -